Thank you, Mr. Chair. I'll carry on with Mr. Nakagawa for a minute, seeing he was the last speaker.
Mr. Nakagawa, do you have a figure that could tell us how much B.C. was spending on its own drug review process before the common drug review? What I'm really looking for is how much is B.C. saving now that the CDR is doing a certain amount of work for it?